Talking stocks, trading, and investing in general - Page 555
We're talking no real volume here other than one big buyer.
IMO I wouldn't be surprised if there are a few shorting algos at work given the constantly low volume. Whoever the buyer is has me impressed with their trading skill.
Brah that's my style -- buy high and sell low.
lol in all seriousness I'm just not liking the senatorial probe into drug pricing. That's a probe into your guys' fundamental business model of acquiring drugs and boosting prices.
No bueno.. I don't see how this ends well.
I think that is a misinterpretation of the business model. List prices are raised, gross prices are very different. As Mike Pearson has said in the last earnings call, buying mispriced assets isn't really in the business model going forward. It hasn't really been part of the strategy over the last few years either.
In general the best way to think of Valeant is as a downstream pharma player rather than the traditional vertically integrated companies. Excellence in commercialization. This also means revenue flow is relatively durable.
And with that, last comment on this!